Private company

Pear Therapeutics (United States)

Pear Therapeutics (United States) is an American health services company based in Boston, incorporated in Delaware.1

Last updated Oct 20, 2026.

Overview

2013Founded1
  • IndustryServices-Health Services1
  • HeadquartersBoston1
  • Websitepeartherapeutics.com
  • Incorporated inDE3
  • Business address200 State Street, 13Th Floor, Boston, Ma 021093
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-971.7%Operating margin4
-594.7%Net margin4
201.7%Revenue growth, 20224
-246.8%Return on equity4
0.00×Debt to equity4
-$117.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue6¢$8.2M
  • Research and development36¢$48.3M
  • Selling, general and admin58¢$79.6M

Out of $12.7M in revenue.4 The company lost money this year.

Financial statements

Revenue54$12.7M in 2022+35% since 2020
0$5.0M$10.0M$15.0M2020: $9.4M$9.4M20202021: $4.2M$4.2M2021−55%2022: $12.7M$12.7M2022+202%
Operating income54-$123.3M in 2022+61% since 2020
-$150.0M-$100.0M-$50.0M02020: -$76.6M-$76.6M20202021: -$105.7M-$105.7M2021+38%2022: -$123.3M-$123.3M2022+17%
Net income54-$75.5M in 2022−22% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$97.0M-$97.0M20202021: -$65.1M-$65.1M2021−33%2022: -$75.5M-$75.5M2022+16%
Fiscal year2019202020212022
Revenue$9.4M5$4.2M4$12.7M4
Cost of revenue$1.7M5$5.2M4$8.2M4
Research and development$28.1M5$37.0M4$48.3M4
Selling, general and admin$56.2M5$67.6M4$79.6M4
Operating expenses$109.9M4$136.0M4
Operating income-$76.6M5-$105.7M4-$123.3M4
Income tax$05$04$04
Net income-$97.0M5-$65.1M4-$75.5M4
Earnings per share-$1.215-$0.574-$0.544
Earnings per share (diluted)-$1.215-$0.574-$0.544
Shares (weighted, basic)113.3M shares4138.7M shares4
Shares (weighted, diluted)113.3M shares4138.7M shares4

Compare Pear Therapeutics (United States) with another company

Corporate structure

Pear Therapeutics (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Pear Therapeutics (United States)

  • JAZZ Human Performance Opportunity Fund, LP Filed SC 13D/A on Pear Therapeutics (United States), latest Apr 28, 2023 (2 filings since Dec 13, 2021)
  • 5AM Ventures IV, L.P. Filed SC 13D/A on Pear Therapeutics (United States), latest Apr 12, 2023 (3 filings since Dec 13, 2021)
  • SB Global Advisers Ltd Filed SC 13G/A on Pear Therapeutics (United States), latest Feb 14, 2023 (3 filings since Dec 13, 2021)
  • CITADEL ADVISORS LLC Filed SC 13G/A on Pear Therapeutics (United States), latest Feb 14, 2022
  • Arboretum Ventures IV, L.P. Filed SC 13G on Pear Therapeutics (United States), latest Dec 13, 2021
  • Corey McCann Filed SC 13D on Pear Therapeutics (United States), latest Dec 10, 2021
  • Temasek Holdings (Private) Ltd Filed SC 13G on Pear Therapeutics (United States), latest Dec 10, 2021
  • LJ10 LLC Filed SC 13G on Pear Therapeutics (United States), latest Dec 8, 2021
  • Pear Therapeutics (United States) Boston

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Pear Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.8M4 Dec 31, 2022$8.6M4 Dec 31, 2021+36.7%
Accumulated depreciation$5.7M4 Dec 31, 2022$2.4M4 Dec 31, 2021+141.1%
Property and equipment, net$6.1M4 Dec 31, 2022$6.3M4 Dec 31, 2021−2.9%
Operating-lease assets (leased space)$8.9M4 Dec 31, 2022$04 Dec 31, 2021

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$48.3M4 Dec 31, 2022$169.6M4 Dec 31, 2021−71.5%
Marketable securities, current$11.0M4 Dec 31, 2022$5.0M4 Dec 31, 2021+119.2%
Debt securities available for sale$11.0M4 Dec 31, 2022$5.0M4 Dec 31, 2021+119.2%

Leadership

Who has led Pear Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Elon Boms2021
  2. Corey McCann2021–2023

Chair

  1. Elon Boms2021

President

  1. Corey McCann2021–2023

Chief financial officer

  1. Joseph Iannotta2021
  2. Christopherd T. Guiffre2021–2023

Chief operating officer

  1. Steven J. Benson2021
  2. Christopherd T. Guiffre2021–2023
201520202025
Board members and other officers (20)

Former names

  • Thimble Point Acquisition Corp.Dec 15, 2020 to Dec 3, 20213

Timeline

  1. Apr 10, 20238-K Listing notice or transfer31
  2. Apr 7, 20238-K Ended a material agreement; Bankruptcy or receivership; Debt or obligation accelerated32
  3. Mar 17, 20238-K Results of operations; Regulation FD disclosure33
  4. Feb 24, 20238-K Executive or director change; Other events34
  5. Jan 3, 20238-K Entered a material agreement35
  6. Nov 14, 20228-K Results of operations; Exit or restructuring costs36
  7. Aug 11, 20228-K Results of operations37
  8. Jul 25, 20228-K Exit or restructuring costs38
  9. Jun 24, 20228-K Regulation FD disclosure39
  10. Jun 15, 20228-K Executive or director change; Shareholder vote; Regulation FD disclosure40
  11. Jun 6, 20228-K Regulation FD disclosure41
  12. May 16, 20228-K Results of operations42
  13. Dec 7, 2021New chief executive Corey McCann becomes CEO9
  14. Feb 1, 2021New chief executive Elon Boms becomes CEO8
  15. 2013Founded Founded1

Calendar

When it reported results

  1. Mar 17, 2023Reported quarterly or annual results33
  2. Nov 14, 2022Reported quarterly or annual results36
  3. Aug 11, 2022Reported quarterly or annual results37
  4. May 16, 2022Reported quarterly or annual results42
  5. Mar 29, 2022Reported quarterly or annual results43
  6. Jan 18, 2022Reported quarterly or annual results44
  7. Jan 11, 2022Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

183 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 22 major events, 95 insider forms, 13 large holders, 47 other. The latest 20:

  1. Apr 28, 2023SC 13D/A EDGAR
  2. Apr 12, 20234 FORM 4 SUBMISSION EDGAR
  3. Apr 12, 2023SC 13D/A EDGAR
  4. Apr 10, 20238-K EDGAR
  5. Apr 7, 20238-K EDGAR
  6. Mar 31, 202310-K EDGAR
  7. Mar 17, 20238-K EDGAR
  8. Feb 24, 20238-K EDGAR
  9. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  11. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  18. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  19. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Feb 17, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

24 open-market trades by officers, directors and large owners since October 2021: 0 buys and 24 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 10, 20235AM Co-Investors IV, L.P.10% ownerSale16,544,113$0.12$2.0MForm 4
Jan 20, 2023O'Brien RonanCCO, GC, & SecretarySale12,162$1.13$13.7KForm 4
Jan 20, 2023Strandberg JuliaChief Commercial OfficerSale12,688$1.13$14.3KForm 4
Jan 20, 2023Brenner Erin K.Chief Product Dev. OfficerSale8,690$1.13$9.8KForm 4
Jan 20, 2023Snow EllenVP, Chief Accounting OfficerSale8,027$1.13$9.1KForm 4
Jan 20, 2023GUIFFRE CHRISTOPHERD TCFO, COO, Treas., & Asst. Sec.Sale19,540$1.13$22.1KForm 4
Jan 20, 2023Maricich YuriChief Medical OfficerSale12,162$1.13$13.7KForm 4
Jan 20, 2023McCann CoreyPresident and CEOSale34,731$1.13$39.2KForm 4
Jan 20, 2023Jeffery KatherineChief People OfficerSale7,096$1.13$8.0KForm 4
Nov 15, 20225AM Ventures IV, L.P.10% ownerSale63,773$2.52$160.7KForm 4
Nov 14, 20225AM Ventures IV, L.P.10% ownerSale12,128$2.79$33.8KForm 4
Nov 11, 20225AM Ventures IV, L.P.10% ownerSale29,380$3.19$93.7KForm 4
Nov 2, 20225AM Partners IV, LLC10% ownerSale10,578$2.72$28.8KForm 4
Nov 1, 20225AM Partners IV, LLC10% ownerSale1,467$2.80$4.1KForm 4
Oct 31, 20225AM Partners IV, LLC10% ownerSale42,164$2.78$117.2KForm 4
Sep 16, 20225AM Opportunities I (GP), LLC10% ownerSale351$1.75$614Form 4
Sep 15, 20225AM Opportunities I (GP), LLC10% ownerSale272,750$1.81$493.7KForm 4
Sep 14, 20225AM Opportunities I (GP), LLC10% ownerSale285,067$1.94$553.0KForm 4
Sep 8, 20225AM Opportunities I, L.P.10% ownerSale304,322$1.81$550.8KForm 4
Sep 7, 20225AM Opportunities I, L.P.10% ownerSale154,518$1.92$296.7KForm 4

All 24 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Pear Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPear Therapeutics, Inc.2
  • CIK0001835567
  • Employer ID (EIN)85-41030922
  • Filer status<br>emerging growth company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)8000 Services-Health Services2
  • Business address200 State Street, 13Th Floor, Boston, MA 021092
  • Phone64693227742
  • Shares outstanding142,739,169 as of Mar 30, 20234
  • Public float$126.8M as of Jun 30, 20224
  • On EDGAR sinceDec 15, 20202
  • Filings219 in all: 4 (75), 3 (27), 8-K (25), 424B3 (13), 425 (12), 10-Q (6), CORRESP (6), EFFECT (6)2
    All 33 form types

    SC 13G (5), UPLOAD (5), S-4/A (3), SC 13D (3), SC 13D/A (3), SC 13G/A (3), 10-K (2), 25-NSE (2), DEFA14A (2), NT 10-Q (2), POS AM (2), S-1 (2), S-8 (2), SEC STAFF LETTER (2), 424B2 (1), 424B5 (1), 8-A12B (1), 8-K/A (1), CERT (1), DEF 14A (1), DRS (1), S-1/A (1), S-1MEF (1), S-3 (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) May 2, 2022
    Latest 8-K (8-K) Apr 10, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53